1RCT2001
Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J · J Clin Endocrinol Metab (2001)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
17 peer-reviewed studies
What the evidence says
Most MK-677 studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 1996–2018 with a typical study size of 24 participants.
Based on 17 studies · 13 RCTs · 135 total participants
Confidence
Moderate confidenceBy outcome
Newest study from 2018
Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J · J Clin Endocrinol Metab (2001)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Copinschi G, Van Onderbergen A, L'Hermite-Balériaux M, Mendel CM, Caufriez A, Leproult R · J Clin Endocrinol Metab (1996)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM · J Clin Endocrinol Metab (1996)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Svensson J, Carlsson B, Carlsson LM, Jansson JO, Bengtsson BA · Clin Endocrinol (Oxf) (1999)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D · J Bone Miner Res (1999)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y · Arch Gerontol Geriatr (2011)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Svensson J, Ohlsson C, Jansson JO, Murphy G, Wyss D, Krupa D · J Bone Miner Res (1998)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Codner E, Cassorla F, Tiulpakov AN, Mericq MV, Avila A, Pescovitz OH · Clin Pharmacol Ther (2001)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML · Neurology (2008)
No plain-language summary recorded for this citation — open the paper to read its abstract.
In plain English: Over 12 months, the ghrelin mimetic MK-677 enhanced pulsatile growth hormone secretion, significantly increased fat-free mass, and was generally well tolerated ... Increased fat-free mass did not result in changes in strength or function.
Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, Heymsfield SB, Bach MA, Vance ML, Thorner MO. · Ann Intern Med (2008)
In plain English: MK-0677 increased serum IGF-1 levels with minimal adverse effects in hemodialysis subjects. Studies are needed to evaluate whether long-term therapy ... improves PEW, lean body mass, physical strength, quality of life and survival.
Campbell GA, Patrie JT, Gaylinn BD, Thorner MO, Bolton WK. · Nephrol Dial Transplant (2018)
In plain English: MK-677 reverses diet-induced nitrogen wasting, suggesting that if these short-term anabolic effects are maintained in patients who are catabolic ... it may be useful in treating catabolic conditions.
Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR. · J Clin Endocrinol Metab (1998)
In plain English: 2-month treatment with MK-677 in healthy obese males caused a sustained increase in serum levels of GH, IGF-I, and IGF-binding protein-3 ... an oral glucose tolerance test showed impairment of glucose homeostasis at 2 and 8 weeks.
Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA. · J Clin Endocrinol Metab (1998)
In plain English: Activation of the ghrelin receptor with MK-0677 inhibited the Aβ burden, neuroinflammation, and neurodegeneration, which suggested that MK-0677 might have potential as a treatment of the early phase of AD.
Jeong YO, Shin SJ, Park JY, Ku BK, Song JS, Kim JJ, Jeon SG, Lee SM, Moon M. · Int J Mol Sci (2018)
In plain English: To date, few long-term, rigorously controlled studies have examined the efficacy and safety of GHSs ... the safety of these compounds with long-term use, including evaluation of cancer incidence and mortality, is needed.
Sigalos JT, Pastuszak AW. · Sex Med Rev (2018)
In plain English: These moderate changes in the proportion non-22K GH isoforms are likely of small importance for the clinical response to MK-677 treatment.
Svensson J, Boguszewski CL, Shibata F, Carlsson B, Carlsson LM, Bengtsson BA. · Growth Horm IGF Res (2003)
In plain English: The non-peptidyl synthetic GHS-R1a agonist, MK0677 ... increased GHS-R1a-mediated intracellular calcium influx.
Schellekens H, McNamara O, Dinan TG, McCarthy JV, McGlacken GP, Cryan JF. · J Pharm Pharmacol (2013)